Clinicopathologic analysis of Fas, Fas ligand, and other biomarkers in locally advanced breast carcinoma

Breast Journal

Volumn 6, Issue 4, 2000, Pages 233-241

  Pernick, Nat L ^a   Biernat, Laura ^c   Du, Wei ^b   Visscher, Daniel W ^a,d  

^a Department of Pathology ^*  (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hematology Oncology Associates East   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Breast carcinoma; Fas (CD95 APO 1 FasR); Fas ligand (CD95L); p53; Preoperative chemotherapy (neoadjuvant, primary)

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; HORMONE RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PARTIAL MASTECTOMY; PREOPERATIVE TREATMENT;

EID: 0033866913     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2000.98087.x     Document Type: Article

References (38)

1. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
2. A role for CD95 ligand in preventing graft rejection
3. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival
4. Fas ligand-induced apoptosis as a mechanism of immune privilege
5. Trophoblasts express Fas ligand: A proposed mechanism for immune privilege in placenta and maternal invasion
6. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
7. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L)
8. Human lung carcinomas express Fas ligand
9. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
10. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
11. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
12. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer
13. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand
14. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
15. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues
16. Fas expression and function in normal and malignant breast cell lines
17. Expression of Fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege
18. The Fas/Fas-ligand system: A mechanism for immune evasion in human breast carcinomas
19. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer
20. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience
21. Multimodality treatment of noninflammatory stage IIIb breast cancer
22. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy
23. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
24. P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer
25. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy
26. Locally advanced breast carcinoma: Accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy
27. Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness
28. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity
29. Sensitization of cancer cells treated with 1 drugs to Fas-mediated cytotoxicity
30. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer
31. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?
32. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance
33. Regulation of the proinflammatory effects of Fas ligand (CD95L)
34. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma
35. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
36. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
37. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
38. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors